The global weight-loss drug market, once dominated by Novo Nordisk, is undergoing a dramatic transformation. On Friday, the ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

Eli Lilly (NYSE:LLY) reported its Q1 2025 ... “neutral” later on would be if a competitor enters the obesity drug treatment market space and starts to eat away at its market share.

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Eli Lilly & Co. (LLY) shares have come under significant pressure in late May following a pivotal decision by CVS Health's ...

As global shortages hit Ozempic and Wegovy, rivals like Eli Lilly gain ground, including in India’s growing market for ...

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.

Novo Nordisk CEO Lars Jørgensen to step down amid increasing pressure from obesity drug competition and recent share price declines.

COPENHAGEN (Reuters) -Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down following a plunge in the company's share price amid intensifying competition in the obesity drug ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...